Grünenthal GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.grunenthal.com
A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body
Phase 1
Completed
- Conditions
- Acute Pain
- Interventions
- Drug: 225 mg GRT0151YDrug: 150 mg GRT0151YDrug: 100 mg GRT0151YDrug: 125 mg GRT0151YDrug: Matching placebo
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT03761407
- Locations
- 🇫🇷
ASTER, Paris, France
Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate
Phase 1
Withdrawn
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Grünenthal GmbH
- Registration Number
- NCT03749733
- Locations
- 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico
A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)
Phase 3
Completed
- Conditions
- Post Herpetic Neuralgia
- Interventions
- Drug: Placebo Plaster
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 265
- Registration Number
- NCT03745404
Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 106
- Registration Number
- NCT03737656
- Locations
- 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico
Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction
Phase 3
Completed
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 1151
- Registration Number
- NCT03714672
- Locations
- 🇲🇽
Private Clinic, Puebla, Mexico
🇲🇽University, San Luis Potosí, Mexico
A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced
Not Applicable
Terminated
- Conditions
- Surgical IncisionLacerationsWounds and Injuries
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 107
- Registration Number
- NCT03688880
- Locations
- 🇫🇷
004 - CHU Amiens-Picardie, Amiens, France
🇫🇷005 - Hôpital Privé Paul d'Egine, Champigny-sur-Marne, France
🇩🇪010 - Charité Berlin, Berlin, Germany
Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)
Phase 3
Terminated
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Interventions
- Drug: PlaceboDrug: Neridronic acid 100 mg
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 267
- Registration Number
- NCT03560986
- Locations
- 🇺🇸
US446 - Clinical Trial Connection, Cottonwood, Arizona, United States
🇺🇸US453 - Physicians Research Group II, LLC, Tempe, Arizona, United States
🇺🇸US428 - Quality of Life Medical and Research Center LLC, Tucson, Arizona, United States
Efficacy and Safety of Intravenous Neridronic Acid in CRPS
Phase 3
Terminated
- Conditions
- Complex Regional Pain Syndrome (CRPS)
- Interventions
- Drug: Neridronic acid 100 mgDrug: Placebo
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 182
- Registration Number
- NCT03530345
- Locations
- 🇺🇸
US015 - Tennessee Valley Pain Consultants, Huntsville, Alabama, United States
🇺🇸US043 - Horizon Research Partners, Mobile, Alabama, United States
🇺🇸US045 - Holland Center for Family Health, Peoria, Arizona, United States
A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
Phase 1
Terminated
- Conditions
- Anesthesia, LocalAnesthesiaAnalgesia
- Interventions
- Combination Product: Neosaxitoxin combined with bupivacaine low (T2)Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine (T1)Combination Product: Bupivacaine low combined with epinephrine (C1)Combination Product: Neosaxitoxin combined with epinephrine (T4)Combination Product: Bupivacaine high combined with epinephrine (C2)Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrineCombination Product: Neosaxitoxin combined with bupivacaine low
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 242
- Registration Number
- NCT03399435
- Locations
- 🇳🇱
NL001, Groningen, Netherlands
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
Phase 1
Withdrawn
- Conditions
- Opioid-Related DisordersPain, AcutePain, Postoperative
- Interventions
- Drug: GRT7014 - Abuse Deterrent Tablet
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Grünenthal GmbH
- Registration Number
- NCT03137017
- Locations
- 🇺🇸
US001: PRA Health Sciences, Lenexa, Kansas, United States